FT Vest U.S. Equity Deep Buffer ETF - November (DNOV)

On our options desk, we are looking closely at DNOV's positioning as it operates mid-period through November 2026. With the underlying SandP 500 trading at a forward P/E near 20.8x—well above the broad-market blended 18.1x—the available upside cap of 12.93% feels compressed relative to historical baseline expectations. Investors entering right now need to recognize they are getting a modified payoff rather than the clean headline metrics established back at the November 2025 reset.

As a risk manager evaluating structured outcome ETFs, the mechanics of DNOV's buffer deserve careful attention. The fund seeks to absorb losses between -5% and -30% over the active period ending November 20, 2026, using custom FLEX options on the SPDR SandP 500 ETF Trust. However, holders should keep the 0.85% total expense ratio in mind, which creates a slight drag on net outcomes compared to holding the physical options structures independently.

Looking at the liquidity and trading metrics for DNOV, total net assets sit near $392.69 million with approximately 7.68 million shares outstanding. Daily volume has been running around 9,709 shares with an average 30-day daily volume of 5,590 shares, alongside a tight 30-day median bid/ask spread of 0.14%. This suggests orderly secondary market activity on the Cboe BZX exchange, though position sizing should account for block creation units.

From a quantitative perspective, running the MF2-GARCH volatility model on DNOV shows interesting leverage dynamics. Recent model outputs point to a 1-day volatility prediction around 4.68% and a 1-month forecast near 5.95%. Crucially, the parameter estimates highlight a strong leverage effect where volatility responds almost entirely to negative shocks, while the ARCH response to positive shocks remains negligible.

When analyzing the technical architecture of First Trust's Target Outcome Strategies, DNOV's inception price of $30.55 back in November 2019 contrasts starkly with its recent closing market price around $51.19. Analysts must verify that any backtesting accounts for the specific outcome period boundaries—in this case, November 24, 2025, to November 20, 2026—to avoid misinterpreting interim mark-to-market valuations as final target payoffs.